» Articles » PMID: 3275523

A Clinical Trial of Buprenorphine: Comparison with Methadone in the Detoxification of Heroin Addicts

Overview
Publisher Wiley
Specialty Pharmacology
Date 1988 Jan 1
PMID 3275523
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of buprenorphine and methadone was compared in the outpatient detoxification of heroin addicts. Forty-five patients were randomized to receive either sublingual buprenorphine or oral methadone under double-dummy and double-blind conditions to study the pharmacology of buprenorphine in a 90-day detoxification protocol. The patients were administered either 2 mg buprenorphine or 30 mg methadone for 3 weeks followed by 4 weeks of dose reductions and 6 weeks of placebo medication. No significant between-group differences were seen on measures of treatment retention, drug use, or symptom report. During the hydromorphone challenge, methadone attenuated opioid effects to a greater extent than did buprenorphine on both physiologic (pupil constriction) and self-report measures. However, this did not result in greater abuse of illicit opioid drugs by subjects taking buprenorphine. The results of this clinical trial indicated that buprenorphine was acceptable to patients and as effective as methadone in the detoxification treatment of heroin addicts.

Citing Articles

Nociceptive Flexion Reflex Threshold is No Suitable Marker for Diagnosing Opioid-Induced Hyperalgesia.

Trubenbacher L, Lindenberg N, Graf B, Backmund M, Unglaub W, Lassen C J Pain Res. 2024; 17:1067-1076.

PMID: 38505502 PMC: 10948325. DOI: 10.2147/JPR.S421841.


History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.

Heidbreder C, Fudala P, Greenwald M Drug Alcohol Depend Rep. 2023; 6:100133.

PMID: 36994370 PMC: 10040330. DOI: 10.1016/j.dadr.2023.100133.


Using machine learning to study the effect of medication adherence in Opioid Use Disorder.

Warren D, Marashi A, Siddiqui A, Eijaz A, Pradhan P, Lim D PLoS One. 2022; 17(12):e0278988.

PMID: 36520864 PMC: 9754174. DOI: 10.1371/journal.pone.0278988.


Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials.

Bergen A, Baurley J, Ervin C, McMahan C, Bible J, Stafford R Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409790 PMC: 8998781. DOI: 10.3390/ijerph19074106.


Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.

Lim J, Farhat I, Douros A, Panagiotoglou D PLoS One. 2022; 17(3):e0266142.

PMID: 35358261 PMC: 8970369. DOI: 10.1371/journal.pone.0266142.